卢丹逸

职称：副教授

学位：博士

E-mail: ludanyi@gzucm.edu.cn

简介：药理学硕士生导师，广州中医药大学杏林人才，分子节律与代谢研究所党支部书记。主持国家自然科学基金和广东省自然科学基金等项目12项，已以第一或通讯作者在Phytomedicine、Biochemical Pharmacology和Drug Metabolism and Disposition等期刊发表SCI论文20篇，作为共同作者在Cell Metabolism和Nature Nanotechnology等期刊发文多篇，获广东省百名博士博士后创新人物、广东省药理学会科技成果奖二等奖等。兼任广东省生物医学工程学会重症医学工程分会青年委员会副主任委员、广东省药理学会药物代谢专业委员会委员、Chinese Herbal Medicines青年编委、Metabolism and Target Organ Damage青年编委等，Advanced Science、MedComm、Journal of Medicinal Chemistry和Biochemical Pharmacology等期刊审稿专家。

教育、工作经历：

2021-01至今，    广州中医药大学，中药学院，副教授/副研究员

2019-09至2020-12，暨南大学，药学院，副研究员

2017-07至2019-08，中国科学院深圳先进技术研究院，博士后/助理研究员

2014-09至2017-06，暨南大学，药学院，博士

2011-09至2014-06，暨南大学，药学院，硕士

2007-09至2011-06，湖南中医药大学，药学院，学士

研究方向：

1）时间药理学；

2）具有调控生物节律功能的分子筛选及应用；

3）药物代谢与药物动力学。

承担课程：

《生物药剂学与药物动力学》、《中药毒理学》

科研及教学课题：

1. 国家自然科学基金-面上项目，2026-01至2029-12，49万元，主持

2. 国家自然科学基金-青年科学基金，2019-01至2021-12，21万元，主持

3. 广东省自然科学基金-青年提升项目，2023-01至2025-12，30万元，主持

4. 广东省自然科学基金-面上项目，2021-01至2023-12，10万元，主持

5. 广东省自然科学基金-博士启动，2018-05至2021-04，10万元，主持

6. 中国博士后科学基金-特别资助，2018-06至2019-08，15万元，主持

7. 中国博士后科学基金-面上资助，2017-11至2019-08，5万元，主持

8. 广州市科技计划项目，2022-04至2024-03，5万元，主持

9. 深圳市科技计划项目，2019-04至2021-03，50万元，主持

10. 深圳市科技计划项目，2018-03至2020-03，50万元，主持

11. 广东省普通高校重点领域专项，2024-10至2027-10，5万元，主持

12. 广东省中医药局科研项目，2021-01至2022-12，1万元，主持

代表性论文：

1.Yongbin Tong^#, Qi Zhang^#, Yutong Chen, Zhiqiang Zhao, Jingqi Li, Jinyi Wang, Haishan Xia, Danyi Lu^*, Yuyu Liu^*. The nuclear receptor REV-ERBα regulates coumarin hepatotoxicity via DBP-dependent repression of CYP2A5 in mice. Expert Opinion on Drug Metabolism & Toxicology. 2025. In press.

2.Dihao Xie, Simin Zhong, Meixue Luo, Jiahao Xu, Ruoyan Zheng, Jiading Luo, Yiting Wang, Yongxing Guo, Lianxia Guo, Baojian Wu^*, Danyi Lu^*. Disruption of local circadian clocks in aristolochic acid-induced nephropathy in mice. Phytomedicine. 2024.135:156235.

3.Caimei Wu^#, Meixue Luo^#, Dihao Xie, Simin Zhong, Jiahao Xu, Danyi Lu^*. Kinetic characterization of estradiol glucuronidation by liver microsomes and expressed UGT enzymes: The effects of organic solvents. European Journal of Drug Metabolism and Pharmacokinetics. 2024.49(3):343-353.

4.Chunhong Wu^#, Yifei Xiao^#, Caimei Wu^#, Dihao Xie, Meixue Luo, Dingyi Yao, Min Chen^*, Danyi Lu^*. Regulation of BCRP expression and sulfasalazine pharmacokinetics by the nuclear receptor REV-ERBα. Xenobiotica. 2023. 53(3):215-222.

5.Luyao Ma^#, Meiping Huang^#, Guanghui Sun, Yanke Lin, Danyi Lu^*, Baojian Wu^*. Puerariae lobatae radix protects against UVB-induced skin aging via antagonism of REV-ERBα in mice. Frontiers in Pharmacology. 2022.13:1088294.

6.Danyi Lu, Zhigang Wang^*, Baojian Wu^*. Pharmacokinetics-based Chronotherapy. Current Drug Metabolism. 2022. 23(1):2-7.

7.Yi Wang^#, Zhigang Wang^#, Zhengping Wu, Menglin Chen, Dong Dong, Pei Yu, Danyi Lu^*, Baojian Wu^*. Involvement of REV-ERBα dysregulation and ferroptosis in aristolochic acid I-induced renal injury. Biochemical Pharmacology. 2021.193: 114807.

8.Meiqing Li^#, Danyi Lu^#, Yulian Cheng^#, Chunlei Wu, Jianchao Zhang, Wenli Shi, Zhihao Ding, Yanyan Li, Binghua Cheng, Xian Lin, Ximing Shao, Hongchang Li, Lijing Fang*, Ke Liu*, Wu Su*. A novel pyrrole-imidazole polyamide targets Aurora kinase A and suppresses tumor growth in vivo. Biochemical and Biophysical Research Communications. 2021.571:167-173.

9.Wenli Shi^#, Danyi Lu^#, Chunlei Wu, Meiqing Li, Zhihao Ding, Yanyan Li, Binghua Chen, Xian Lin, Wu Su, Ximing Shao, Zhihui Xia, Lijing Fang^*, Ke Liu^*, Hongchang Li*. Coibamide A kills cancer cells through inhibiting autophagy. Biochemical and Biophysical Research Communications. 2021.547:52-58.

10.Huan Zhao, Yongbin Tong, Danyi Lu^*, Baojian Wu^*. Circadian clock regulates hepatotoxicity of Tripterygium wilfordii through modulation of metabolism. Journal of Pharmacy and Pharmacology. 2020.72(12):1854-1864.

11.Danyi Lu^#, Mengjing Zhao^#, Min Chen, Baojian Wu^*. Circadian clock-controlled drug metabolism: Implications for chronotherapeutics. Drug Metabolism and Disposition. 2020.48(5):395-406. (封面论文)

12.Danyi Lu^#, Dong Dong^#, Qian Xie, Zhijie Li, Baojian Wu^*. Disposition of mianserin and cyclizine in UGT2B10-overexpressing human embryonic kidney 293 cells: identification of UGT2B10 as a novel N-glucosidation enzyme and breast cancer resistance protein as an N-glucoside transporter. Drug Metabolism and Disposition. 2018.46(7):970-979.

13.Danyi Lu, Dong Dong^*, Baojian Wu^*. Highly selective N-glucuronidation of four piperazine-containing drugs by UDP-glucuronosyltransferase 2B10. Expert Opinion on Drug Metabolism & Toxicology. 2018.14(9):989-998.

14.Danyi Lu, Shuai Wang, Qian Xie, Lianxia Guo, Baojian Wu*. Transcriptional regulation of human UDP-Glucuronosyltransferase 2B10 by farnesoid X receptor in human hepatoma HepG2 cells. Molecular Pharmaceutics. 2017.14(9):2899-2907.

15.Danyi Lu^#, Qian Xie^#, Baojian Wu^*. N-glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: Assay optimization and substrate identification. Journal of Pharmaceutical and Biomedical Analysis. 2017.145:692-703.

16.Danyi Lu^#, Hui Liu^#, Wencai Ye, Ying Wang, Baojian Wu^*. Structure- and isoform-specific glucuronidation of six curcumin analogs. Xenobiotica. 2017.47(4):304-313.

17.Dong Dong^#, Tianpeng Zhang^#, Danyi Lu^#, Jie Liu, Baojian Wu^*. In vitro characterization of belinostat glucuronidation: demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes. Xenobiotica. 2017.47(4):277-283.

18.Danyi Lu^#, Zhiguo Ma^#, Tianpeng Zhang, Xingwang Zhang, Baojian Wu^*. Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1. Xenobiotica. 2016.46(1):1-13.

19.Danyi Lu^#, Dong Dong^#, Zhong Liu, Yifei Wang^*, Baojian Wu^*. Metabolism elucidation of BJ-B11 (a heat shock protein 90 inhibitor) by human liver microsomes: identification of main contributing enzymes. Expert Opinion on Drug Metabolism & Toxicology. 2015.11(7):1029-40.

20.Danyi Lu, Jiayu Zhang, Zhenya Yang, Hongming Liu, Sha Li, Baojian Wu^*, Zhiguo Ma^*. Quantitative analysis of Cistanches Herba using high-performance liquid chromatography coupled with diode array detection and high-resolution mass spectrometry combined with chemometric methods. Journal of Separation Science, 2013, 36(12): 1945-1952.

代表性著作/教材：

1.《Circadian Pharmacokinetics》，Springer Nature，2020年10月，共同主编

2.《生物钟与药代动力学》，科学出版社，2020年6月，第一副主编

3.《生物药剂学与药物动力学》，中国中医药出版社，2023年9月，编委

发明专利：

1. 马志国，杨振亚，李承花，卢丹逸，一种沙苁蓉提取物及其制备方法和应用，2015.06.03，中国，ZL201310168868.8。

2. 李红昌，粟武，房丽晶，卢丹逸，张建超，刘科，一种Aurora A蛋白抑制剂及其制备方法和药物用途，2020.07.03，中国，ZL201910339972.6。

3. 吴宝剑，卢丹逸，孙小雅，吴彩媚，人NR1D1报告基因质粒、稳转细胞株及其构建方法和应用，2022.04.24，中国，ZL202210449409.6

4. 吴宝剑，卢丹逸，吴彩媚，谢迪豪，罗美雪，王帅，张天鹏，石吊兰素在制备脂肪肝防治药物中的应用，2023.09.26，中国，CN202311248138.9

5. 吴宝剑，王帅，杨熠，卢丹逸，岩豆素在制备治疗谵妄相关认知障碍药物中的应用，2023.10.18，中国，CN202311345864.2

6. 张天鹏，吴宝剑，李杏嫦，杨宇，刘健，喻芳君，卢丹逸，一种治疗时差综合征的中药组合物及其制备方法，2024.05.15，中国，CN202410603187.8